RMD
data caveat$44.8BCF+
ResMed
Sleep & respiratory
Global leader in cloud-connected devices for sleep apnea and out-of-hospital respiratory care (CDIs on ASX)
Data HealthTrials14 of 19 active · stale enrollment
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$0.0M
Dec 2025 4C
Runway
CF+Cash Flow Positive
Based on Dec 2025 4C
Market Cap
$44.8B
Burn Rate
—
Dec 2025 4C
Shares Outstanding
1.5B
Pipeline Assets
4
Latest Insight(1)
13 Apr 2026substantial_holderBecoming a substantial holder
New holder·AustralianSuper Pty Ltd·5%
3M Price
RMD.ASX$30.760-19.9% 3M
Low $30.760High $38.550
Pipeline Assets (4)
AirSense 11Obstructive sleep apnea (CPAP)
ApprovedAirCurve 11Central/complex sleep apnea (BiPAP)
ApprovedAstralLife support ventilation (invasive/non-invasive)
ApprovedmyAir / AirViewDigital health platform (remote patient monitoring)
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Transactions
20 transactionsLast 90dNet Sell
Buys1+1 vs prior
Sells15+13 vs prior
Buy Value$731k
Sell Value$8652k
warningMichael J. Farrell bought 24d before "Trial data readout — Circadian Rhythm Monitoring Study" ($730,687)
warningMichael J. Farrell bought 55d before "Trial data readout — Evaluation of a Wearable PAP Device in a Tethered Configuration for the Treatmen" ($730,687)
OPTIONS EXERCISEMichael J. Farrellopen_in_new
Substantial Holders (5%+ threshold)
1 noticeINITIALAustralianSuper Pty Ltd
5.00%2026-04-09
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
7 competitor trialsPhase 2+ · Non-ASX
Obstructive Sleep Apnea (Cpap)7 active trials
2 Ph42 Ph31 Ph22 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
14 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
J Am Soc Mass Spectrom2026-04· Astral
Proteomics2026-04· Astral
Anal Chim Acta2026-04· Astral
J Agric Food Chem2026-04· Astral
Catalysts (100)· 10 upcoming · 90 past
SpeculativeremoveMed1 May 2026
SpeculativeremoveMed1 June 2026
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Filing discipline not scored — this company reports under US regime (Form 10-K / 10-Q). ASX Listing Rule 4.7C deadlines don't apply.
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
★ RESULTS
Clinical Trials(36)
19 activeClinicalTrials.gov ↗
RecruitingOBSERVATIONALEnrollment stale · 811d
Registry Study on Prescription, Patient Pathways, Therapy Efficacy and Usage of Mandibular Advancement Devices in Obstructive Sleep Apnea - PATT-OSA Registry
Obstructive Sleep Apnea
18 Years – 99 Years
Primary endpoint Changes of the Apnoea-Hypopnea-Index (AHI) at baseline compared to a follow-up after 3 months
RecruitingOBSERVATIONALEnrollment stale · 1377d
CPAPMAD
Long-term Benefits of CPAP or MAD Treatment on the Sleep of OSAS Patients
OSA
18 Years – 80 Years
Primary endpoint To determine the evolution of deep slow-wave sleep at one year in OSA patients according to the treatment initiated by continuous positive pressure or mandibular advancement device (MAD).
NARecruitingEnrollment stale · 377d
Investigational algorithmControl algorithm
Evaluation of a Novel Auto-Adjusting Positive Airway Pressure Algorithm for the Treatment of Obstructive Sleep Apnea Clinical Study
Obstructive Sleep Apnea
RandomizedSingle Blind18 Years+
Primary endpoint Comparison of the algorithm efficacy (AHI) to a clinically relevant data
Announcements(8)
person
Insider Tradeauto_awesome
4 Statement of changes in beneficial ownership9 Apr 2026
expand_more192KB
person
Insider Tradeauto_awesome
4 Statement of changes in beneficial ownership6 Apr 2026
expand_more10KB